Clinical Trial Update: Safety and Efficacy of Exenatide as Monotherapy [Phase 3]

View source ↗

Summary

This document reports the completion of a Phase 3 trial evaluating exenatide as monotherapy for type 2 diabetes, detailing its safety and efficacy outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• EXENATIDE (EXENATIDE)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED